Analysis of FcgammaRIIA cytoplasmic tail requirements in signaling for serotonin secretion: evidence for an ITAM-dependent, PI3K-dependent pathway.
The human Fc receptor, FcgammaRIIA, is known to mediate phagocytosis and endocytosis, yet the greatest numbers of these receptors are expressed on the surface of non-phagocytic platelets, where they are involved in serotonin secretion. FcgammaRIIA harbours three tyrosine (Y) residues within its cytoplasmic domain. Y1 is upstream of both Y2 and Y3, which are contained within an immunoreceptor tyrosine-based activation motif (ITAM), required for many signaling events. We have demonstrated that the two ITAM tyrosines are required for phagocytic signaling and that mutation of a single ITAM tyrosine decreases but does not abolish phagocytic signaling. Furthermore, we have identified that the YMTL motif is required for endocytosis. These observations suggest that FcgammaRIIA utilizes different sequences for various signaling events. Therefore, we investigated the sequence requirements for another important FcgammaRIIA-mediated signaling event, serotonin secretion, using Rat Basophilic Leukemia (RBL-2H3) cells transfected with wildtype (WT) FcgammaRIIA or mutant FcgammaRIIA. Stimulation of cells expressing WT FcgammaRIIA induced release of serotonin at a level 7-fold greater than that in nonstimulated WT FcgammaRIIA-transfected cells or nontransfected RBL cells. Mutation of either ITAM tyrosine (Y2 or Y3) to phenylalanine was sufficient to abolish serotonin secretion. Further, while inhibition of Syk with piceatannol blocked phagocytosis as expected, it did not inhibit serotonin secretion. Additionally, inhibition of phosphoinositol-3-kinase (PI3K) with wortmannin only had a partial effect on serotonin signaling, despite the fact that the concentrations used completely abolished phagocytic signaling. These data suggest that the requirements for serotonin secretion differ from those for phagocytosis mediated by FcgammaRIIA.
Daniels
A B
AB
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Worth
R G
RG
Dickstein
R J
RJ
Dickstein
J S
JS
Kim-Han
T-H
TH
Kim
M-K
MK
Schreiber
A D
AD
D000818:Animals; D001792:Blood Platelets / Q000378:metabolism*; D045744:Cell Line, Tumor; D003593:Cytoplasm / Q000378:metabolism; D010587:Phagocytosis / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D017452:Receptors, IgG / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D014162:Transfection
C080568:Fc gamma receptor IIA; D017452:Receptors, IgG; D012701:Serotonin; D019869:Phosphatidylinositol 3-Kinases; D011505:Protein-Tyrosine Kinases
Exp Hematol. 2006 Nov;34(11):1490-5
17046568
J Immunol. 1992 Aug 15;149(4):1365-73
1386863
Immunol Lett. 1995 Jan;44(2-3):133-8
7797242
EMBO J. 2002 Feb 1;21(3):251-8
11823418
FEBS Lett. 1997 Jan 2;400(1):11-4
9000504
Blood. 2003 Nov 15;102(10):3637-45
12893767
Blood. 1995 Dec 15;86(12):4389-99
8541526
Blood. 1994 Sep 15;84(6):1753-9
7521687
J Biol Chem. 1999 Jan 22;274(4):1898-904
9890943
Blood. 2000 Nov 15;96(10):3439-46
11071639
J Biol Chem. 1998 Sep 18;273(38):24314-21
9733717
Blood. 2008 Oct 1;112(7):2780-6
18641368
J Clin Invest. 1991 Nov;88(5):1766-71
1834702
Atherosclerosis. 2006 Mar;185(1):173-6
16005880
J Immunol. 1994 Jan 1;152(1):270-9
7504712
J Biol Chem. 2003 Jan 31;278(5):3331-8
12424246
Blood. 1998 Mar 1;91(5):1762-8
9473244
Biochim Biophys Acta. 1999 Oct 13;1452(1):46-59
10525159
J Biol Chem. 1999 Nov 12;274(46):32662-6
10551821
Exp Hematol. 1999 May;27(5):875-84
10340404
J Immunol. 1999 Dec 15;163(12):6785-93
10586078
Annu Rev Immunol. 1997;15:203-34
9143687
J Immunol. 1999 Dec 1;163(11):6123-31
10570302
EMBO J. 1994 Jul 1;13(13):2963-9
8039492
J Biol Chem. 1994 Nov 25;269(47):29697-703
7961959
J Cell Biol. 1994 Aug;126(4):991-1004
8051216
J Immunol. 2001 Jul 15;167(2):844-54
11441091